This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher (TMO) on its progress with COVID-19-related products and services.
Quest Diagnostics' (DGX) Volumes Aid, Price Pressure Stays
by Zacks Equity Research
According to Quest Diagnostics (DGX), the delay of the 2022 PAMA cuts announced last year proved beneficial for the industry and Medicare beneficiaries.
QIAGEN (QGEN) QuantiFeron Hits New Sales Landmark in TB Testing
by Zacks Equity Research
According to QIAGEN (QGEN), QuantiFERON is different from other IGRA tests based on its efficient workflow.
Quest Diagnostics' (DGX) New Contract to Aid COVID-19 Research
by Zacks Equity Research
Quest Diagnostics' (DGX) COVID-19 serological tests, nationwide reach and data analytics capabilities will help assess COVID-19 vulnerability throughout the country.
Here's Why You Should Invest in Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in the Animal Health business and dental business.
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $300.02, moving +0.03% from the previous trading session.
Should Value Investors Consider McKesson (MCK) Stock Now?
by Zacks Equity Research
Let's see if McKesson (MCK) stock is a good choice for value-oriented investors right now from multiple angles.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.
Fresenius Medical's (FMS) Merger Deal to Improve Kidney Care
by Zacks Equity Research
Fresenius Medical's (FMS) merger deal to build an independent entity to transform kidney care and health equity throughout the United States.
Integra (IART) Debuts NeuraGen 3D for Peripheral Nerve Repair
by Zacks Equity Research
Integra's (IART) NeuraGen 3D will provide surgeons with access to the latest technology in peripheral nerve repair.
Henry Schein (HSIC) Stock Moves Up 16.9%: What's Driving It?
by Zacks Equity Research
Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.
Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe
by Zacks Equity Research
Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.
Humana (HUM) Taps Debt Market With Senior Note Pricing
by Zacks Equity Research
Humana (HUM) exhibits monetary discretion by pricing senior secured notes to procure funds.
Thermo Fisher's (TMO) New Buyouts Aid, Cost Pressure Ails
by Zacks Equity Research
Thermo Fisher's (TMO) high degree of response to the pandemic has enabled it to accelerate its growth strategy, strengthen customer relationships, and bump up investments.
McKesson (MCK) Is Up 6.34% in One Week: What You Should Know
by Zacks Equity Research
Does McKesson (MCK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why You Should Retain Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences' (EW) robust segmental performance and growing product uptake.
Myriad Genetics (MYGN) Makes Progress in Precision Oncology
by Zacks Equity Research
Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.
Walgreens (WBA), Village MD Plan to Expand Into New Hampshire
by Zacks Equity Research
Walgreens (WBA) and VillageMD are working together to make it easier for the communities to access high-quality, coordinated primary care and pharmacy services.
Here's Why You Should Hold on to Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Alcon's (ALC) better-than-expected results and robust segmental performance.
Align Technology (ALGN) Debuts Latest Feature for ClinCheck
by Zacks Equity Research
Align Technology's (ALGN) CBCT integration feature for ClinCheck will enable doctors to treat a broader range of cases with the Invisalign clear aligners.
Reasons to Hold on to Myriad Genetics (MYGN) Stock For Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.
Here's Why You Should Hold on to Insulet (PODD) Stock For Now
by Zacks Equity Research
Investors are optimistic about Insulet's (PODD) robust uptake of the Omnipod system both in the U.S. and international markets.
Here's Why You Should Buy McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.